The control of CD95 expression is a key factor for the regulation of apoptosis in several cellular systems. Although different transcription factors, such as p53, SP-1, NF-kB, GAbinding protein and AP-1 have been implicated in the regulation of CD95 promoter in various cellular contexts, [1] [2] [3] the molecular events regulating constitutive and inducible CD95 gene expression have not been fully elucidated. Interferon-g (IFN-g) increases CD95 expression and CD95-induced apoptosis in several cell types. 4 We hypothesized that such upregulation of CD95 expression and signaling could be mediated by the interferon regulatory factor-1 (IRF-1), a tumor-suppressor transcription factor involved in the immune-regulatory activity of interferons. IRF-1 is induced in response to IFN-g and to a variety of other cytokines, and has been shown to be involved in tumor suppression, growth regulation, cell differentiation and apoptosis. [5] [6] [7] [8] Several studies have contributed to define IRF-1 as a regulator of apoptosis: IRF-1 mRNA is induced by IFN-g earlier and more strongly than other apoptosis-related genes, suggesting a direct involvement of IRF-1 in the transactivation of proapoptotic gene families. Moreover, IRF-1 has been demonstrated to mediate DNA damage-induced apoptosis in mitogenactivated T lymphocytes, a process that does not require p53. 9 Nevertheless, the specific role of IRF-1-inducible genes in IRF-1-dependent apoptotic pathway remains unknown. By using a dedicated computer program, we found two consensus binding sequences for IRF-1 in the human CD95 promoter sequence. In order to verify whether IRF-1 was able to bind the CD95 promoter, we synthesized two doublestranded oligonucleotides whose sequences reproduce the CD95 promoter region encompassing the two putative IRF-1-binding sites. Both probes were 32 P labeled and utilized in electrophoretic mobility shift assay (EMSA) experiments with nuclear extracts obtained from U937 monocytic cells stimulated with IFN-g for 2 h. In Figure 1a , we show the appearance of two inducible IRF-1-binding complexes, whose specificity was demonstrated by competition assays with a molar excess of unlabeled wild-type probe or of an unrelated oligomer. Moreover, an anti-IRF-1 polyclonal antibody was able to induce a supershift that could be abrogated by a specific neutralizing peptide. To assess whether IRF-1 binding plays a functional role in trans-activation of the human CD95 promoter, we performed the luciferase reporter gene assay in a recipient cell system using wild-type and mutated sequences derived from the CD95 promoter. As described in Figure 1b , the CD95 promoter region from nt À1435 to nt +236 and a series of mutants were cloned upstream the luciferase gene in the PGL2 basic vector and the resulting constructs (PGL-CD95, mutant-1, -2 and -3) were transiently cotransfected in TK-ts13 cells together with an IRF-1 expression vector (pAct) or an empty control vector (pActC). The luciferase expression driven by the entire CD95 promoter (PGL-CD95) was enhanced approximately 55 folds in the presence of the IRF-1 expression vector. The mutated CD95 promoter constructs M1 and M2, containing IRF-1-binding site 1 and IRF-1-binding site 2, respectively, were both specifically trans-activated by IRF-1, although to a lesser extent (about 14 folds). As expected, the M3 construct, a deletion mutant without any IRF-1-binding site, was not substantially activated by IRF-1. In order to understand the role of IRF-1 in CD95 gene regulation, we analyzed the kinetics of IRF-1 and CD95 mRNA induction by IFN-g in peripheral blood-derived human monocytes and in U937 monocytic cells. After total RNA isolation, quantitative real-time RT-PCR was performed to evaluate IRF-1 and CD95 mRNA levels in cells stimulated up to 24 h with IFN-g. Target genes (IRF-1 and CD95) were coamplified with the endogenous 18 S gene, and their levels were normalized on the basis of the endogenous control. As shown in Figure 1c , we observed a tight correlation between IRF-1 and CD95 gene expression levels both in monocytes and in U937 cells. This observation suggests the possibility that CD95 levels may be influenced by the amount of IRF-1 present in the cell. In order to investigate the effect of IRF-1 inhibition on CD95 expression, we performed a relative quantification of IRF-1 and CD95 transcript levels in monocytes or U937 cells treated with IRF-1 antisense oligodeoxynucleotides (ODN). In Figure 1d , we show that treatment of monocytes with antisense ODN for 24 h results in about 75% inhibition of IFN-g-induced IRF-1 upregulation, with a consequent significant reduction of CD95 levels. Similar results were obtained in U937 cells. Moreover, the effect of IRF-1 inhibition on CD95 protein expression paralleled the effect on gene expression, as shown by cytofluorimetric analysis in Figure 1e . To investigate the possible role of IRF-1 in CD95-mediated apoptosis, we targeted IRF-1 expression with antisense ODN and evaluated the levels of cell death induced by an agonistic anti-CD95 antibody in U937 cells. Cells were stimulated with IFN-g in the presence or absence of IRF-1 antisense or missense ODN and treated 4 h with anti-CD95 antibody. The percentage of apoptotic cells was determined by the Annexin V-propidium iodide standard assay. According to previous reports, we found that IFN-g stimulation increased CD95-mediated apoptosis of U937 cells. On the other hand, treatment with IRF-1 antisense ODN significantly inhibited CD95-induced cell death, whereas treatment with missense ODN did not reproduce the same effect (Figure 1f ).
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These observations suggest that IRF-1 contributes to IFN-gmediated sensitization of monocytic cells to CD95-induced apoptosis.
CD95 induction by IRF-1, while not being the only event responsible for the proapoptotic activity of IRF-1, may contribute to explain the role of this transcription factor in determining susceptibility to cell death. Since IRF-1 has been demonstrated to mediate caspase-1 gene induction, the proapoptotic activity of IRF-1 has been in some cases ascribed to increased caspase-1 expression and activation. 10 However, whereas the importance of caspase-1 in the production of inflammatory cytokines is widely recognized, its role in apoptosis remains controversial and seems in most cases subordinated to caspase-3 and -8 activation. It has been recently reported that the release of IFN-g by cytotoxic T cells upregulates CD95 expression on the surface of target IFN-g-mediated CD95 upregulation may play a role in the feedback regulation of an immune response by clearing APC that are no more necessary for antigen presentation. In this view, IFN-g released by CTL may activate IRF-1, which would contribute to CD95 upregulation and sensitization of monocytes to CD95-induced apoptosis. Since macrophages derived from IRF-1À/À mice are refractory to cytotoxicity induced by stimulation with LPS plus IFN-g, 12 it would be interesting to investigate the possible involvement of CD95 in this process. Our observation that IRF-1 is able to modulate CD95 levels may have potential implications also in nonhematopoietic cells, particularly where IRF-1 nullizygosity has been shown to determine an increased resistance to pathological cell death. IRF-1 expression is increased after cerebral ischemia in damaged regions of the brain, and IRF-1 knockout mice show a substantial reduction of infarctuated area and neurological deficits. Since CD95 has been reported to mediate ischemia/reperfusion-induced apoptosis, which involves death receptor-mediated damage, it would be interesting to evaluate the possible contribution of IRF-1 to the induction of CD95 expression in ischemic neurons. In conclusion, we provide evidence that IRF-1 plays a role in IFN-g-induced CD95 expression and sensitivity of monocytic cells to CD95-mediated apoptosis. This study may contribute to clarify both the mechanisms that control CD95 expression and the links between IRF-1 and the transcriptional regulation of apoptosis. 
